Αρχική World News FDA Approves Acalabrutinib with Venetoclax for CLL or SLL World News FDA Approves Acalabrutinib with Venetoclax for CLL or SLL Από Ogkologos - 4 Μαρτίου, 2026 428 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Breakfast Ideas 21 Αυγούστου, 2020 Fine Needle Aspiration Biopsy: How to Prepare and What to Expect 7 Οκτωβρίου, 2021 What to Know About Cancer Care and Research for People 65+:... 28 Φεβρουαρίου, 2023 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True 27 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS 10 Ways to Brave Cancer Treatment: Tips from a Survivor Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in... At NCI, A Robust and Rapid Response to the COVID-19 Pandemic